• SPX
  • 6090.27
  • 0.25 %
  • 15.1602
  • DJI
  • 44642.52
  • -0.28 %
  • -123.1914
  • N225
  • 39137.36
  • 0.12 %
  • 46.41
  • FTSE
  • 8308.61
  • -0.49 %
  • -40.7695
  • IXIC
  • 19859.773
  • 0.81 %
  • 159.0508
Annovis Bio, Inc. (ANVS) Stock Price, News & Analysis

Annovis Bio, Inc. (ANVS) Stock Price, News & Analysis

Currency in USD Disclaimer

$5.96

$0.14

(2.4%)

Day's range
$5.8
Day's range
$6.25
50-day range
$5.75
Day's range
$10.54
  • Country: US
  • ISIN: US03615A1088
52 wk range
$4.53
Day's range
$22.49
  • CEO: Dr. Maria L. Maccecchini Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -18.80
  • Piotroski Score 0.00
  • Grade Buy
  • Symbol (ANVS)
  • Company Annovis Bio, Inc.
  • Price $5.96
  • Changes Percentage (2.4%)
  • Change $0.14
  • Day Low $5.80
  • Day High $6.25
  • Year High $22.49

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/27/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $25.50
  • High Stock Price Target $30.00
  • Low Stock Price Target $21.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$5.14
  • Trailing P/E Ratio -1.2
  • Forward P/E Ratio -1.2
  • P/E Growth -1.2
  • Net Income $-56,204,313

Income Statement

Quarterly

Annual

Latest News of ANVS

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Annovis Bio, Inc. Frequently Asked Questions

  • What is the Annovis Bio, Inc. stock price today?

    Today's price of Annovis Bio, Inc. is $5.96 — it has increased by +2.4% in the past 24 hours. Watch Annovis Bio, Inc. stock price performance more closely on the chart.

  • Does Annovis Bio, Inc. release reports?

    Yes, you can track Annovis Bio, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Annovis Bio, Inc. stock forecast?

    Watch the Annovis Bio, Inc. chart and read a more detailed Annovis Bio, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Annovis Bio, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NYSE, exchange stock trades by Annovis Bio, Inc. stock ticker.

  • How to buy Annovis Bio, Inc. stocks?

    Like other stocks, ANVS shares are sold on stock exchanges such as NYSE. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Annovis Bio, Inc.'s EBITDA?

    Annovis Bio, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Annovis Bio, Inc.’s financial statements.

  • What is the Annovis Bio, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Annovis Bio, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Annovis Bio, Inc.'s financials relevant news, and technical analysis. Annovis Bio, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Annovis Bio, Inc. stock currently indicates a “sell” signal. For more insights, review Annovis Bio, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.